Program
GENSCI120
A development code. Also written as “GenSci120”, “GenSci120 150 mg” and “GenSci120 600 mg”.
Its studies are mostly in Arthritis, Rheumatoid · Autoimmune Diseases, led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 32 open or running | phase 2since Feb 4, 2026 | Jan 22, 2025 | Sep 2027phase 2 · NCT07423533 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 22, 2025First study: phase 1 study in Autoimmune DiseasesFirst studyNCT06827457 · 58 enrolled · China
- Jun 10, 2025Phase 1 study in Arthritis, RheumatoidNCT07040930 · 30 planned · China
- Feb 4, 2026Phase 2 study in Arthritis, RheumatoidPhase 2 reachedNCT07423533 · 450 planned · China
Ahead
- Sep 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07423533
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07423533Arthritis, Rheumatoid · China | 2 | Recruiting | Sep 2027 | 450 |
| NCT07040930Arthritis, Rheumatoid · China | 1 | Recruiting | Jul 5, 2026 | 30 |
| NCT06827457Autoimmune Diseases · China | 1 | Completed | Nov 27, 2025 | 58 |
How it is read
Names in the registry
- “GenSci120”, 2 entries
- “GenSci120 150 mg”, 1 entry
- “GenSci120 600 mg”, 1 entry
- “GenSci120 1000 mg”, 1 entry
Codes read as this program: GENSCI120.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 2 studies
- Autoimmune Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.